Matinas Biopharma (NYSEAMERICAN:MTNB) Trading 0.4% Higher – Here’s What Happened

Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) traded up 0.4% on Friday . The company traded as high as $0.25 and last traded at $0.2340. Approximately 2,402,845 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 14,997,717 shares. The stock had previously closed at $0.2330.

Matinas Biopharma Price Performance

The company has a market cap of $1.50 million, a P/E ratio of -0.20 and a beta of 1.76. The firm’s 50-day moving average is $0.49 and its two-hundred day moving average is $0.57.

Get Matinas Biopharma alerts:

Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) EPS for the quarter.

Institutional Trading of Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 11.77% of the company’s stock.

About Matinas Biopharma

(Get Free Report)

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.

Recommended Stories

• Five stocks we like better than Matinas Biopharma
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.